On the other hand, pre-clinical mouse models with head and neck cancer show that absence of FAP positive CAF surprisingly did not affect tumour progression or sensitise tumours to combination cisplatin and anti-PD1 treatment. The gene discussed is FAP; the disease is head and neck cancer.